Clinical Competition Candidate
GILENYA
GILENYA carries use-code patent, low complexity (1/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 18 months away. Active clinical competition may compress the generic entry window.
LOE window
18months
to latest listed patent expiry (December 25, 2027)
Expiry attractiveness: 4/5
Patent profile
Substance patent (none)
Product / formulation patent (none)
Use-code patent (listed)
Patent count: 1
Complexity score: 1/5
Clinical competition
Score: 5/5
Active trials linked: 150
Phase 2/3 trials: 51
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: FINGOLIMOD HYDROCHLORIDE
Applicant (NDA holder): NOVARTIS PHARMACEUTICALS CORP
Confidence: High